Dr. Jeffrey Edward Miller ‘87, founder and CEO of Invivoscribe, has been named the recipient of the 2025 UCLA Chemistry & Biochemistry Alumni Award.
Miller will accept the award and present the commencement address at the UCLA Chemistry & Biochemistry graduation ceremony on Saturday, June 14, 2025.
“The eleven years I spent studying and working in laboratories at UCLA were essential in ensuring my long-term success,” Miller said. “Hands-on lab work at UCLA taught me the skills required to identify opportunities and direct scientific projects. My time at UCLA also resulted in close personal relationships, which I have enjoyed for almost five decades; UCLA quite simply changed the course of my life.”
Miller is the Founder and CEO of Invivoscribe, a global leader in molecular diagnostics and precision medicine. He has spent most of his career advancing diagnostics in the fields of oncology, specifically developing the standardized tests, bioinformatics, and technologies used to identify and track hematologic malignancies. Under his leadership, Invivoscribe has assisted in getting multiple targeted oncology drugs approved and continues to develop cutting-edge technologies that improve cancer treatment outcomes worldwide. A proud UCLA alumnus, Miller has dedicated his career to translating innovative research into clinically impactful solutions. Recognized as a key figure in biotechnology, he continues to drive advancements in precision diagnostics, shaping the future of healthcare.
